Remifentanil as Intravenous Patient-controlled Analgesia (IVPCA) During Labour
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
Remifentanil is a ultra short-acting synthetic opioid. It is rapidly metabolized by
non-specific blood and tissue esterases. We wanted to investigate the efficacy and safety of
remifentanil used as analgesia during labour. Intravenous patient controlled analgesia
(ivpca) were used to administer remifentanil. Doses used were 0,15-1,05 mikrogr/kg, with a
lock-out time of 2 minutes. 41 women were included in the study. Blood-pressure, heartrate,
SaO2, respiration rate and sedation were recorded every 15.minute. Fetal heart rate was
recorded for the whole periode of treatment (CTG, STAN). Vaginal contraction pain were
assessed by the parturients every 15.minute using a Visual Analogue Scale (VAS). Midwives
also recorded their impression of the parturients pain. The parturients level of sedation
were recorded by anesthesiologist and midwife every 15.minute. Apgar scores were registered
at 1, 5 and 10 min after delivery. Umbilical cord blood analysis regarding blood gases and
concentration of remifentanil were performed. After delivery, both mother and midwife
evaluated efficacy and safety; Global satisfaction score, if the remifentanil doses were
sufficient, nausea, vomiting, level of sedation and dizziness.